Advertising medicines direct to consumers: mere information or subtle persuasion?
The advertising of medicines available on prescription has always been the subject of argument. It has recently been criticised because of the rather doubtful matter of how much emphasis should be placed upon possible side-effects as compared with likely benefits. Some cyclo-oxygenase-2-inhibitors, notably rofecoxib, have
had to be withdrawn from the market because of possible toxic risks and others,
like celecoxib, have become controversial. Some litigation has raised the accusation
that direct-to-consumer advertising has involved misrepresentation.
In the New England Journal of Medicine for 17 January, Ernst Berndt of the Massachusetts
Institute of Technology has examined the question of how far drug advertising
to consumers may proceed to persuade them, rather than merely inform them, regarding
their choice of a remedy. There must always be a controversial element in advertising,
but it takes on new proportions when it concerns health matters.
The evaluations of physicians regarding advertising directly to consumers are
mixed, writes Dr Berndt, with 40 per cent believing that it helps prescribers
in their practice, 30 per cent that its effect is negative and 30 per vent that
it has no effect at all. However, it appears that there is strong support from
patients for direct advertising. As they face increasing charges for drugs, patients
feel a right to demand more information from the manufacturers.
Nevertheless, advertising may not only inform; it also tends inevitably to add
an element of persuasion. Part of the problem is the inadequacy of the information
offered. Direct advertisements make drugs seem better than in fact they are.
A better balance of warnings against recommendations seems to be called for.
Yet the question arises, how far a reader of information who cannot have inside
knowledge of the jargon may be relied upon to make a sound interpretation of
what is presented.
Back to Top
|